Search

Financial analysis of Drug industry securities is given. Securities performance is outlined through graphs, charts and forecasting data.

The performance of pharmaceutical industry stocks has been poor in the year 2002 due to the operating environment. Few companies are prepared for the costly product development process the industry requires, but profit growth should improve in the future. Few of these stocks are timely for the year 2002.

Drug industry stocks ended lower in the 4th qtr of 2002 as industry fundamentals declined. Industry consolidation may continue in the future, and the aging populations of Europe, Japan, and the US should increase demand for pharmaceuticals. Investors need to be selective with these stocks.

The drug industry is expected to have a good year in 2002, although the year 2001 was not a good one for the industry. The year 2002 will also be a transitional one for the industry, with the industrial nation's aging population needing more medications. These stocks are timely for investors in the year 2002.

The pharmaceuticals industry has done well in the year 2001 in spite of the slower US economy and the Sep 11, 2001 terrorist attacks. However, the lapse of patents presents a challenge to many drug companies. These stocks are timely for 2001 and the next three to five years.

Stock prices for the US drug industry have remained strong in the first half of the year 2001, with many at all-time highs. Product demand is keeping profits healthy, but there are some problems with several companies. This industry's stocks are timely for investors in 2001.

The drug industry had a good year in 1999 and the year 2000 is also expected to be profitable, although earnings will be slightly lower. The industry is also consolidating and the debate over Medicare in the presidential campaign in the year 2000 will also have an affect on the industry. Investors need to seek those stocks with good margins and rising product lines.

Earnings and profits for the drug industry have been good for the second half of 1999 and this trend is expected to continue for the next ten years, as well, price hikes have a better environment, also. However, some drugs are losing patent protection in the coming years, and drug industry stock prices have fallen during 1999. These stocks are timely for investors due to good earnings and demographic trends in 1999 and later.

Operational basics and earnings for the pharmaceutical industry remain good for 1999 and this scenario is expected to remain in place for the near-term future. However, the stocks in this industry have declined in their timeliness rating, due in part to sector rotation into cyclical issues, despite the 19.9% increase in the Dow Jones Industrial Average since the beginning of 1999. Investors need to seek the highest quality stocks during periods of price weakness in this industry.

Stocks in the pharmaceutical industry are timely in 1999 and are expected to outperform the market with good earnings growth, revenue gains from volume and other factors. However, investment trends on Wall Street, current valuations, and economic developments in Asia and elsewhere have called the industry's bull market into question. Investors need to be cautious as this sector has compression and other risks, even though its earnings are likely to remain high for several years.

The pharmaceutical industry had good earnings in 1998 and profits were sharply higher, and this is expected to continue through 1999 although not at the previous pace. The stocks in this industry surged higher in 1998, also, with most of them beating the Standard and Poor's 500 index, as investors were seeking quality issues in this sector. The dynamics of these stocks are not attractive in 1999, however, even though investors can find some favorable issues.

Prices for drug stocks soared between Aug 1994 and Aug 1995, but the trend toward vertical and horizontal consolidation that is occurring in the industry will place a premium on investing in large multinational companies that offer a wide array of new medicines and have the wherewithal to fund research and development. Overall, drug stocks are no longer cheap and only a few have attractive rankings.

ICN Pharmaceuticals's 2003 and 2004 earnings estimates may have to be reduced as optimistic although it is making progress towards long-term earnings. There are too many unknowables for deriving meaningful alternatives.

Valeant Pharmaceuticals bought back three million shares held by HealthCor Management for $96.75 million on 19 November 2009 as part of its long-running buyback program. The buyback was an off-exchange, unbrokered deal and avoided moving the stock price.

The shares of Valeant Pharmaceuticals International could fall in value as the company struggles to offset declining royalties from the antiviral drug ribavirin by sales from the epilepsy drug retigabine. Share prices could fall by a up to one-third from $33.66 a share.

The price appreciation potential of the shares of Valeant Pharmaceuticals for the years 2011-2013 is discussed. The Costa Mesa, California-based company manufactures drugs and other medical products.

The shares of Valeant Pharmaceuticals have trended downward over the years and their pipeline products are not likely to change the company's prospects. The Costa Mesa-based company manufactures anti-infectives, dermatologicals, vitamins, and vision care products.

The price appreciation potential of the shares of Valeant Pharmaceutical for the years 2010-2012 is discussed. The Costa Mesa, California-based company is a manufacturer of drugs and other medical products.

A comparative analysis of the company sales and earnings and the financial details of Valeant Pharmaceuticals from 1988 - 2003 are illustrated. Projections of the equity price of this company for 2004 - 2005 is made using Value Line estimates.

Information on the investor groups Iridian Asset Management and Franklin Mutual Advisers' position on ICN Pharmaceuticals Inc's management following their investments in the company is offered. Additional information on both groups' demands regarding ICN's management restructuring is included.